The following will not impact the stock price. It is interesting for the future of INSM, once iPlex production occurs. This option is not subject to the Ipsen settlement as IGFBP-3 is already off patent.
PLoS One. 2013;8(1):e55084. Epub 2013 Jan 28.
IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis.
Mohanraj L, Kim HS, Li W, Cai Q, Kim KE, Shin HJ, Lee YJ, Lee WJ, Kim JH, Oh Y.
In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.